The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
about
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associationsOptimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature.Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.
P2860
Q36160774-51242407-CD9B-47FD-99C9-95207F10C602Q38740314-428779D8-1FCE-4865-A1C3-A484C8798FF8Q41214544-0F99CAB3-1BF0-43EA-8168-77CA28970671Q42395601-DE771076-ADA6-4D2A-859D-33768970B25BQ49524483-18CBB8E8-4D6A-46A7-B354-F60F8C41C5BCQ55286218-E721072A-6B99-4E1F-9002-2DC644027B45Q55518414-A8B59D14-80F1-4CC2-81F3-70FD6BA4D45B
P2860
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Best. First. Anti-EGFR bef ...... cancer: from bench to bedside.
@en
type
label
The Best. First. Anti-EGFR bef ...... cancer: from bench to bedside.
@en
prefLabel
The Best. First. Anti-EGFR bef ...... cancer: from bench to bedside.
@en
P2860
P1476
The Best. First. Anti-EGFR bef ...... cancer: from bench to bedside.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00280-016-3032-8
P577
2016-04-18T00:00:00Z
P6179
1024473585